
Find Reports
Select Report Type
Reimbursement Review
Displaying 1151 - 1175 of 1422
Please scroll or swipe to the right to view the full content.
Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Reviews Update ... | |||||||||
HR positive, HER2 negative bre... | HR positive, HER2 negative breast cancer | Complete | PH0053-000 | ||||||
durvalumab, olaparib, carbopla... | Imfinzi, Lynparza | durvalumab, olaparib, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair proficient (pMMR) | Withdrawn | PC0366-001 | ||||
teprotumumab | TBC | teprotumumab | Thyroid Eye Disease (TED), chronic | Active | SR0853-001 | ||||
delgocitinib | TBC | delgocitinib | Chronic hand eczema | Received | SR0875-000 | ||||
Pharmaceutical Reviews Update ... | |||||||||
Non-small cell lung cancer (NS... | Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation | Complete | PH0054-000 | ||||||
datopotamab deruxtecan | TBC | datopotamab deruxtecan | advanced or metastatic non-squamousnon-small cell lung cancer (NSCLC) | Cancelled | PC0384-000 | ||||
masitinib mesylate | Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | SR0766-000 | ||||
osilodrostat | Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | SR0804-000 | ||||
risperidone | TBC | risperidone | Schizophrenia, adults | Suspended | SR0811-000 | ||||
ibrutinib | Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0004-000 | |||
Pharmaceutical Reviews Update ... | |||||||||
Multiple Myeloma | Multiple Myeloma | Complete | PH0047-000 | ||||||
Large B cell lymphoma | Large B cell lymphoma | Complete | PH0048-000 | ||||||
Prostate Cancer | Prostate Cancer | Active | PH0050-000 | ||||||
Cutaneous Melanoma | Cutaneous Melanoma | Complete | PH0049-000 | ||||||
donanemab | TBC | donanemab | Alzheimer's disease | Suspended | SR0857-000 | ||||
galcanezumab | Emgality | galcanezumab | Episodic cluster headache | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0019-000 | |||
clofarabine | Clolar | clofarabine | Acute lymphoblastic leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0020-000 | |||
dapagliflozin | Forxiga | dapagliflozin | Chronic kidney disease | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0021-000 | |||
Rivaroxaban (granules for oral... | Xarelto | Rivaroxaban (granules for oral suspension) | Venous Thromboembolic Events | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0022-000 | |||
glecaprevir / pibrentasvir | Maviret | glecaprevir / pibrentasvir | Hepatitis C, chronic | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0023-000 | |||
sofosbuvir / velpatasvir | Epclusa | sofosbuvir / velpatasvir | Hepatitis C, chronic | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0024-000 | |||
fluticasone furoate/umeclidini... | Trelegy Ellipta | fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | Asthma, maintenance | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0025-000 |
Health Technology Review
Displaying 576 - 600 of 600
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1151 - 1175 of 2132
Please scroll or swipe to the right to view the full content.